Anglo French Drugs Unlisted Shares
Anglo French Drugs and Industries Ltd.
INE570E01016
Incorporation Date: 01-Feb-1923
Listing Status: DRHP Not Filed
Listed On Metropolitan Stock Exchange
About Anglo French Drugs Unlisted Shares
Overview of Anglo French Drugs Unlisted Shares
Anglo-French Drugs & Industries Limited
1. About Company
Anglo-French Drugs & Industries Limited (AFDIL) is an Indian pharmaceutical company established in 1923. Headquartered in Bengaluru, Karnataka, the company develops, manufactures and markets pharmaceutical formulations for domestic and international markets.
The company has a long-standing presence in the pharmaceutical industry, with expertise in vitamins, nutritional healthcare products, injectables and therapeutic medicines. Its product portfolio covers several therapeutic areas, including central nervous system disorders, cardiovascular conditions, respiratory ailments, infections and general wellness.
AFDIL aims to provide quality medicines through its pharmaceutical manufacturing capabilities, established brands, distribution network and international marketing operations.
2. Introduction & Manufacturing Infrastructure
AFDIL's pharmaceutical manufacturing operations are centred in Bengaluru, Karnataka. The company has developed its manufacturing capabilities over several decades, expanding from pharmaceutical trading and distribution into the production of a broad range of formulations.
Its manufacturing infrastructure supports the production of tablets, capsules, liquid formulations, injectables, ointments and other pharmaceutical preparations. The company also maintains quality assurance systems to monitor product quality throughout manufacturing.
In 2024, the company upgraded its tableting facility at Peenya Industrial Estate, Bengaluru, with the objective of modernising operations and meeting relevant international manufacturing compliance requirements, including PIC/S and EAEU-related standards.
3. Business Model & Operational Verticals
Pharmaceutical Formulations Manufacturing: AFDIL manufactures finished pharmaceutical products in different dosage forms, including tablets, liquids, capsules, injectables and topical preparations. These products are marketed under its own brands and supplied through distribution channels.
Domestic Pharmaceutical Marketing: The company markets medicines across India through its pharmaceutical divisions, distributors, chemists and other healthcare distribution channels.
Export Business: AFDIL exports pharmaceutical products to international markets. Its export operations have expanded from initial registrations in Russia to a presence across countries in Eastern Europe, Southeast Asia and Africa.
Optima Division: The Optima division focuses on making the company's medicines available across India at affordable prices. It offers products across multiple therapeutic segments through the domestic distribution network.
Franchise and Distribution Network: The company works with independent distributors and franchise partners to extend the availability of selected brands, particularly in smaller towns and locations that may be less accessible to conventional distribution channels.
Quality Assurance and Regulatory Compliance: Quality monitoring, manufacturing standards and regulatory compliance are integral to its production and marketing operations.
4. Key Product & Therapeutic Portfolio
Vitamins and Nutritional Healthcare: Vitamin formulations, B-complex preparations and nutritional supplements designed to address nutritional deficiencies and support general wellness.
Central Nervous System Medicines: Products used in the management of selected neurological and psychiatric conditions.
Cardiovascular Medicines: Formulations intended for the treatment of selected heart and circulatory conditions.
Anti-Infective Medicines: Pharmaceutical products used in the treatment of bacterial, fungal and other infections, depending on the specific formulation.
Anti-Malarial Products: Medicines used in the treatment and management of malaria.
Respiratory and Cold Remedies: Products for cough, cold and selected respiratory symptoms.
Gastrointestinal Medicines: Formulations used for acidity, gastric disorders and related digestive conditions.
Injectables and Liquid Formulations: Injectable medicines, syrups, elixirs and other liquid pharmaceutical preparations.
Topical Preparations: Ointments, creams and other formulations intended for external application.
Haematinics and Iron Supplements: Products formulated to support the management of iron deficiency and related nutritional requirements.
5. Brands & Product Development
AFDIL has established a portfolio of pharmaceutical brands across nutritional healthcare and multiple therapeutic categories.
Its recognised product brands include Beplex, associated with vitamin and B-complex formulations, alongside products such as Maximin, Codylex, Alcrin and other medicines serving specific therapeutic requirements.
The company continues to develop and introduce products across its existing therapeutic segments. Its product strategy focuses on meeting healthcare needs through established brands, formulation development and wider domestic and international distribution.
6. Technology, Quality & Regulatory Capabilities
AFDIL maintains manufacturing and quality assurance capabilities to support the consistent production of pharmaceutical formulations. Its quality systems monitor products at different stages of manufacturing, helping maintain compliance with applicable pharmaceutical standards.
The company has undertaken manufacturing facility upgrades to modernise production processes and improve its ability to serve regulated export markets. Its tableting facility upgrades in 2024 were directed towards compliance with relevant international manufacturing requirements.
Regulatory compliance, product quality, process control and manufacturing consistency remain important elements of the company's operating model.
7. Management & Corporate Structure
AFDIL operates as a publicly listed pharmaceutical company and has been associated with the Kanoria Group since 1985, when the group acquired a controlling interest in the business.
The company is managed through its board of directors and executive leadership, which oversee business strategy, manufacturing, pharmaceutical marketing, exports, regulatory compliance and corporate governance.
Its business structure supports domestic pharmaceutical operations alongside international marketing and distribution activities.
8. Industry & Business Ecosystem
AFDIL operates in India's pharmaceutical formulations industry, which supplies medicines across a wide range of therapeutic categories. Demand is influenced by healthcare access, disease prevalence, physician prescriptions, pharmacy distribution and increasing awareness of preventive healthcare and nutrition.
The company's business ecosystem includes pharmaceutical ingredient suppliers, packaging vendors, distributors, stockists, chemists, doctors, hospitals, regulatory authorities and international pharmaceutical customers.
In export markets, product registration, manufacturing compliance, regulatory approvals and local distribution relationships are important factors influencing market access and business expansion.
9. Key Business Highlights
Established Pharmaceutical Heritage: Began operations in 1923 and has a long history in pharmaceutical manufacturing and marketing.
Manufacturing Base in Bengaluru: Operates pharmaceutical formulation facilities, including its Peenya manufacturing facility.
Broad Therapeutic Portfolio: Offers products across vitamins, nutritional healthcare, central nervous system, cardiovascular, anti-infective, respiratory and gastrointestinal categories.
Established Product Brands: Maintains recognised brands such as Beplex, Maximin, Codylex and Alcrin.
Domestic Distribution Reach: Uses its Optima division and distribution and franchise networks to improve product availability across India.
International Presence: Exports pharmaceutical products to markets across Eastern Europe, Southeast Asia and Africa.
Manufacturing Modernisation: Upgraded its tableting facilities in 2024 to support operational improvements and relevant international compliance requirements.
Quality-Focused Operations: Emphasises manufacturing quality assurance, regulatory compliance and continued product development.
Insights of Anglo French Drugs Unlisted Shares
Anglo French Drugs and Industries Ltd.
Based on the standalone profit and loss figures provided for FY26 and FY25. All figures are in ₹ crore.
1. Financial Highlights
| Particulars | FY26 | FY25 | YoY Change |
|---|---|---|---|
| Net Revenue | 90.32 | 87.79 | +2.9% |
| Total Operating Cost | 99.59 | 105.02 | -5.2% |
| EBITDA | -9.27 | -17.23 | Loss narrowed |
| EBITDA Margin | -10.3% | -19.6% | +9.3 pp |
| Other Income | 29.80 | 12.97 | +129.8% |
| Depreciation & Amortisation | 39.07 | 30.20 | +29.4% |
| Finance Costs | 26.53 | 9.71 | +173.3% |
| Profit Before Tax (as reported) | 1.74 | 0.00 | — |
| Profit from Continuing Operations | -0.05 | 0.71 | Turned loss-making |
| Profit from Discontinuing Operations | 22.81 | 7.22 | +215.9% |
| Total Profit for the Period | 22.81 | 7.22 | +215.9% |
pp = percentage points. Percentage changes are calculated from the supplied figures.
2. Key Financial Insights
- Modest revenue growth: Revenue increased by 2.9%, from ₹87.79 crore to ₹90.32 crore, indicating limited sales growth.
- Operating losses narrowed: EBITDA loss reduced from ₹17.23 crore to ₹9.27 crore. Operating costs declined by 5.2% despite higher revenue, and the EBITDA margin improved from -19.6% to -10.3%.
- Higher other income: Other income more than doubled to ₹29.80 crore. This is an important contributor to reported profitability, and its underlying source should be examined to assess whether it is recurring.
- Depreciation and finance costs increased: Depreciation rose by 29.4%, while finance costs increased by 173.3% to ₹26.53 crore. These expenses may continue to pressure earnings.
- Continuing operations remained weak: The company reported a loss of ₹0.05 crore from continuing operations, compared with a profit of ₹0.71 crore in FY25.
- Discontinued operations drove reported profit: Profit from discontinued operations increased to ₹22.81 crore from ₹7.22 crore. This contribution is material to the overall result and should be separated from the performance of the continuing business.
3. Important Data Reconciliation
The supplied figures contain inconsistencies that need verification against the original financial statements:
FY26 profit before tax of ₹1.74 crore does not reconcile with the reported profit before tax and exceptional items of ₹2.02 crore plus exceptional items of ₹24.51 crore.
FY26 profit from continuing operations of -₹0.05 crore plus discontinued-operations profit of ₹22.81 crore equals ₹22.76 crore, rather than the reported total profit of ₹22.81 crore.
The FY25 profit before tax, income tax and continuing-operations profit figures also do not reconcile cleanly.
These differences should be checked before the figures are used in a formal report.
4. Key Takeaways
Revenue increased by 2.9% in FY26.
EBITDA losses narrowed by approximately 46.2%, indicating improved operating performance.
Other income increased significantly, while depreciation and finance costs also rose.
Discontinued operations contributed substantially to the reported profit.
The continuing business remains under pressure, and the supplied profit and tax figures require reconciliation.
Financial Charts of Anglo French Drugs Unlisted Shares
Balance Sheet of Anglo French Drugs Unlisted Shares
Profit and Loss of Anglo French Drugs Unlisted Shares
Ancillary of Anglo French Drugs Unlisted Shares
Ratio Analysis
Peers
Industry Benchmarking
Segment Revenue
Subsidaries
Security Allotment
Corporate Governance
Team Management Details
FAQs of Anglo French Drugs Unlisted Shares
-
How to buy Anglo French Drugs and Industries Ltd.?
Below are three ways through which you can purchase Anglo French Drugs and Industries Ltd.:
- We at Altius Investech have many actively traded scripts and are market makers of unlisted shares. To check out all the unlisted shares traded. (Click on link). To submit a request to buy Anglo French Drugs and Industries Ltd., please click on the trade button at the top of this page
- Additionally, you can download our app from your play store or app store, register on our application, and engage in active trading there.
Download the Altius App here https://onelink.to/hf4m72 - You can also reach out to us at : +91 8240614850 / +91 8240861716
-
How to sell Anglo French Drugs and Industries Ltd.?
Below are three ways through which you can sell Anglo French Drugs and Industries Ltd.:
- We at Altius Investech have many actively traded scripts and are market makers of unlisted shares. To check out all the unlisted shares traded. (Click on link). To submit a request to sell Anglo French Drugs and Industries Ltd., please click on the trade button at the top of this page
- Additionally, you can download our app from your play store or app store, register on our application, and engage in active trading there.
Download the Altius App here https://onelink.to/hf4m72 - You can also reach out to us at : +91 8240614850 / +91 8240861716
-
What is the price of Anglo French Drugs and Industries Ltd.?
We provide a two way quote on all the shares we deal in. Your buy price for Anglo French Drugs and Industries Ltd. is ₹2666 and your sell price for Anglo French Drugs and Industries Ltd. is ₹1000. The price is based on our estimates and market conditions.
-
What is the lock-in period of Anglo French Drugs and Industries Ltd.?
The lock-in period for Anglo French Drugs and Industries Ltd. varies depending on the category of investors:
- For retail Investors, HNIs, or Body Corporates, the lock-in period is 6 months from the date of the listing of Anglo French Drugs and Industries Ltd.
- For Venture Capital Funds or Foreign Venture Capital Investors, there is a lock-in period of 6 months from the date of acquisition of Anglo French Drugs and Industries Ltd.
- For AIF-II (Alternative Investment Funds - Category II), there is no lock-in period
August 2021 saw the introduction of this regulation by SEBI. The purpose of the regulation change, which lowered the lock-in period from a year to six months, was to incentivize additional investments in firms getting ready for initial public offerings, or IPOs. Since its introduction, a number of Portfolio Management Services (PMS) have advised their clients to purchase Pre-IPO shares in order to take advantage of the advantages associated with early-stage investments. This reduction in the lock-in period is considered as a significant step forward.
-
How is the Anglo French Drugs and Industries Ltd. price calculated?
Fundamental & Comparative valuation models and the forces of demand and supply in the market for unlisted shares dictate the price. These prices are based on our estimates and transaction history of Anglo French Drugs and Industries Ltd.. The price is also determined from the most recent funding round for Anglo French Drugs and Industries Ltd.. This provides us with a benchmark valuation, offering a clear indication of the company's current market value as perceived by investors and industry experts.
-
What are the lot sizes of Anglo French Drugs and Industries Ltd.?
We can generally arrange lot sizes starting with an investment of INR 20,000. To confirm the lot sizes of Anglo French Drugs and Industries Ltd. with us kindly click here.
-
What are the financials of Anglo French Drugs and Industries Ltd.?
The financials of Anglo French Drugs and Industries Ltd. which includes the P/L of Anglo French Drugs and Industries Ltd. and the Balance Sheet of Anglo French Drugs and Industries Ltd. is in the financials section (Click on link).
-
Where can I find the annual report of Anglo French Drugs and Industries Ltd.?
The annual report of Anglo French Drugs and Industries Ltd. is available in the annual report section (Click on link).
-
Is buying Anglo French Drugs and Industries Ltd. legal in India?
Yes, buying and selling unlisted shares in India is indeed 100% legal. This activity is regulated and governed under the guidelines provided by the Securities and Exchange Board of India (SEBI). Investors and traders must adhere to these regulations and guidelines to ensure compliance with legal and financial standards. It's important for participants in the unlisted share market to be aware of and understand these regulations to engage in transactions legally and securely.
-
Short-term Capital Gain taxes to be paid on Anglo French Drugs and Industries Ltd.?
When you sell unlisted shares within a period of two years from the date of acquisition, any profit earned from the sale is classified as Short-term Capital Gain (STCG). This gain is then added to your total income for that financial year. The tax on this short-term capital gain is calculated based on your applicable individual income tax slab rates. Therefore, the rate at which you will pay tax on the STCG from unlisted shares depends on your total income, including this gain, and the tax slab it falls under as per the prevailing income tax laws in India. It's important for investors to consider these tax implications when engaging in transactions involving unlisted shares.
-
Long-term Capital Gain taxes to be paid on Anglo French Drugs and Industries Ltd. and how are They Taxed?
Long-term Capital Gains (LTCG) on unlisted shares in India refer to the profits earned from the sale of unlisted shares that have been held for more than two years. The key aspects of LTCG on unlisted shares include:
- Tax Rate: LTCG on unlisted shares is taxed at a rate of 20%.
- Indexation Benefit: This is a significant advantage for investors. Indexation allows for adjusting the purchase price of the shares for inflation, which can reduce the taxable gain.
- Importance for Investors: Understanding LTCG is crucial, especially for High Net-worth Individuals (HNIs) and retail investors, as it impacts their investment strategy and tax planning. Knowing these details helps in making informed investment decisions.
- Calculation: LTCG is calculated by subtracting the indexed cost of acquisition (the purchase price adjusted for inflation) from the sale price of the shares. The profit thus calculated is subject to a 20% tax.
- Applicability: LTCG tax is applicable to profits from the sale of unlisted shares held for more than two years.
- Relevance: This tax is particularly relevant to investors in the unlisted share market, including those considering selling their holdings after a period of more than two years.
-
Applicability of Taxes on Anglo French Drugs and Industries Ltd. once it is listed?
When shares initially bought in the unlisted market become listed, the taxation rules change significantly if these shares are sold through a stock exchange. Here's what investors need to know:
Transition to Listed Market Tax Rates: Once unlisted shares are listed on the stock exchange and subsequently sold, the tax rates applicable to listed securities come into effect. This shift means that the favourable tax treatments for listed shares, as per the prevailing tax laws, will apply.
Taxation Based on Holding Period: The crucial factor in determining the type of capital gains tax (Long-term or Short-term) is the holding period of the shares. Importantly, this period is calculated from the original purchase date when the shares were unlisted.
Long-term vs. Short-term Capital Gains: If the shares are sold after being held for more than one year from the date of purchase (including the period when they were unlisted), they are subject to Long-term Capital Gains (LTCG) tax.
Conversely, if sold within one-year, Short-term Capital Gains (STCG) tax rates apply.
Significance for Investors: This information is vital for investors in the unlisted market, as it impacts their tax planning and decision-making process. Understanding these nuances ensures that investors can strategically plan the sale of their shares post-listing to optimize tax implications.
Advice for Investors: It's advisable for investors to keep a record of their purchase dates and monitor the listing dates closely. Additionally, staying updated with the latest tax regulations or consulting with a financial advisor is recommended for accurate tax calculations and compliance. -
How does Altius Investech source Anglo French Drugs and Industries Ltd.?
At Altius Investech, our approach to sourcing Anglo French Drugs and Industries Ltd. unlisted shares involves a strategic and direct method. Primarily, we acquire these shares from the below key groups:
Employees of the Company: Employee stock option plans (ESOPs) or other compensation packages frequently include shares for firm employees. For a various reasons, such as including portfolio diversification or financial considerations, some of these employees may eventually choose to sell their shares. We engage with these employees, providing them a platform to sell their shares.
Initial Investors: These are the angel or early-stage investors who provided capital to the business in its early stages. These original investors may look to sell all or part of their ownership position in the company as it develops and flourishes. This might be done for various reasons such as in order to maximise their investment, reallocate resources, or make other calculated financial decisions.
Funding rounds and VC funds: Altius Investech sources the shares from private placement rounds in which private companies seek to obtain capital from the market. Through our platform, venture capital funds can liquidate their shares and we receive the inventory from them when they decide to sell a portion of their ownership through block trades.
By establishing connections with these groups, Altius Investech guarantees our clients a steady and dependable supply of Anglo French Drugs and Industries Ltd. unlisted shares. This process not only makes it easier for employees and initial investors in liquidating their assets, but it also gives our clients access to shares that aren't often found on the open market. Our platform effectively facilitates a win-win situation for both buyers and sellers. -
How to trust Altius Investech before buying Anglo French Drugs and Industries Ltd. from its platform?
Altius Investech stands at being India's fastest growing and leading marketplace for buying and selling unlisted shares. We believe in enabling access to alternative sources of investments at lower entry barriers to private equity investments.
With more than 25 years of experience, Altius Investech has carved a niche in the financial market by serving more than 8000 clients. The incredible journey is further highlighted by the vast number of transactions that Altius Investech has facilitated transactions that have already exceeded 300 crores.
For investors Altius Investech curates investment opportunities in companies at reasonable valuations which are on the verge of an IPO leading to massive value unlocking. Investments are backed by thorough research and sound investment thesis, with a time bound exit plan.
For ESOP Shareholder and existing Investors, we assist them to liquidate their shares even if they are not publicly traded by creating a platform where we find the right buyers and sellers for the best prices.
Altius Investech have been featured in top media news outlets like Economic Times, Financial Express, Money control. Check out about us on these - leading publications (Click on link) Our journey over these years has not just been about numbers; it's been about building trust and reliability.
We at Altius Investech are dedicated to upholding the greatest levels of ethics and transparency, making sure that your investment experience is not only profitable but also safe and reliable.
Press of Anglo French Drugs Unlisted Shares
Featured Blogs of Anglo French Drugs Unlisted Shares
Annual Report of Anglo French Drugs Unlisted Shares
Company Information of Anglo French Drugs Unlisted Shares
Featured Companies


